Sacituzumab govitecan: observed
17 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsRecruitingNCT07610616Report a problem
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic ResponseRecruitingNCT07582887Report a problem
- Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingNCT07551050Report a problem
- Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World StudyRecruitingNCT07251868Report a problem
- Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast CancerRecruitingNCT07066917Report a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
- Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker ExplorationRecruitingNCT06991790Report a problem
- A Real World Study of Sacituzumab GovitecanRecruitingNCT06966141Report a problem
- Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast CancerRecruitingNCT06877416Report a problem
- Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast CancerNot yet recruitingNCT06798506Report a problem
- To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.RecruitingNCT06784921Report a problem
- Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingNCT06356519Report a problem
- Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world StudyRecruitingNCT06240195Report a problem
- Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerActive, not recruitingNCT07018427Report a problem
- Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab GovitecanCompletedNCT06504719Report a problem
- Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related ToxicitiesCompletedNCT05349383Report a problem
- Expanded Access for IMMU-132Approved for marketingNCT04320693Report a problem